Ironwood Pharmaceuticals Overview
- Founded
-
1998

- Status
-
Public
- Employees
-
219

- Stock Symbol
-
IRWD

- Share Price
-
$12.01
- (As of Tuesday Closing)
Ironwood Pharmaceuticals General Information
Description
Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
Contact Information
- 100 Summer Street
- Suite 2300
- Boston, MA 02110
- United States
Ironwood Pharmaceuticals Stock Performance
(As of Tuesday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$12.01 | $11.91 | $10.13 - $14.21 | $1.82B | 153M | 3.43M | $1.08 |
Ironwood Pharmaceuticals Financials Summary
In Thousands, USD |
TTM 30-Jun-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
---|---|---|---|---|
EV | 1,717,142 | 1,804,020 | 1,964,369 | 2,383,287 |
Revenue | 415,637 | 413,753 | 389,523 | 428,413 |
EBITDA | 236,101 | 232,604 | 140,399 | 98,263 |
Net Income | 173,100 | 528,448 | 106,176 | 21,505 |
Total Assets | 975,690 | 1,126,927 | 559,238 | 402,748 |
Total Debt | 416,084 | 475,802 | 453,702 | 431,222 |
Ironwood Pharmaceuticals Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Ironwood Pharmaceuticals Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
Ironwood Pharmaceuticals Comparisons
Industry
Ironwood Pharmaceuticals Competitors (31)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
OrphoMed | Venture Capital-Backed | San Francisco, CA | 00 | 000.00 | 00000000000 | 000.00 |
0000000 0000000000 | Formerly VC-backed | Cambridge, MA | 0000 | 00.000 | 0000 | 00.000 |
0000000 000000000 | Formerly VC-backed | Tel Aviv, Israel | 000 | 00000 | 000000000 | 00000 |
000000000 00000000 | Private Equity-Backed | San Diego, CA | 000 | 00000 | 0000000 0000 | 00000 |
0000000000 0000000 | Formerly VC-backed | San Diego, CA | 000 | 00000 | 000000&0 |
Ironwood Pharmaceuticals Patents
Ironwood Pharmaceuticals Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20210261690-A9 | Method of generating anti-linaclotide antibodies and uses thereof | Abandoned | 11-May-2018 | 000000000 | |
AU-2018302255-A1 | Efficacy of a gastro-retentive bile acid sequestrant dosage form | Pending | 19-Jul-2017 | 0000000000 | |
US-20200138854-A1 | Method of detecting and quantifying bile acid from saliva | Abandoned | 19-Jul-2017 | 0000000000 | |
CA-3070082-A1 | Efficacy of a gastro-retentive bile acid sequestrant dosage form | Pending | 19-Jul-2017 | 0000000000 | |
EP-3654953-A4 | Efficacy of a gastro-retentive bile acid sequestrant dosage form | Pending | 19-Jul-2017 | A61K31/785 |
Ironwood Pharmaceuticals Executive Team (30)
Ironwood Pharmaceuticals Board Members (23)
Name | Representing | Role | Since |
---|---|---|---|
Alexander Denner Ph.D | Self | Board Member | 000 0000 |
Andrew Dreyfus | Self | Board Member | 000 0000 |
Benjamin Cravatt Ph.D | Self | Board Member, Advisory Team | 000 0000 |
Catherine Moukheibir | Self | Board Member | 000 0000 |
Edward Owens | Self | Board Member | 000 0000 |
Ironwood Pharmaceuticals Signals
Ironwood Pharmaceuticals Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|